John Padfield, previously a board director of Amersham and CEO of Chiroscience, is appointed to board of Akubio as chairman
Akubio, the acoustic detection technology company, has announced
the appointment of John Padfield as chairman of its board.
Padfield was previously a board director of Amersham and CEO of
Commenting on his new position, Dr Padfield said:
"Akubio has achieved a major breakthrough in molecular
detection by developing acoustic technology that can detect the
sounds that molecular bonds make when they break.
has significant advantages over existing technologies with
tremendous potential across many applications including in
diagnostics, and pharmaceutical and life science research.
forward to working with the board and management team to achieve
commercial success." Dr Padfield brings to Akubio extensive
experience in both the biotech and pharmaceutical industries.
Currently he serves as a non executive director on several boards
including Lorantis and Profile Therapeutics.
Over the last ten
years he has gained extensive, global, public board-level
experience: until December 2002 he was CEO of Amersham Health and
a board director of FTSE 100 company Amersham; between 1998 and
2002 he was on the board of IntraBiotics Pharmaceuticals; and he
served for five years as CEO of Chiroscience until its merger
with Celltech in 1999.
Prior to this he held a variety of senior
positions within Glaxo for over 15 years.
In addition to his
commercial roles, Dr Padfield is a leading figure on public and
industry bodies: presently he is a council member of the UK
Biotechnology and Biological Sciences Research Council (BBSRC)
and he was a director and chairman of the UK BioIndustry
Association (BIA) from 1995 to 1999.
With the addition of Dr
Padfield Akubio's board consists of John Pritchard, CEO,
Matthew Cooper, CSO, Stephen Bunting, Tim Rink, John Shields,
David Klenerman, and Bill Matthews.
Welcoming Dr Padfield, Dr
Pritchard said: "We are delighted to have attracted a
chairman of Dr Padfield's calibre to Akubio.
This is an
endorsement of Akubio's innovative technology.
experience ranges from managing biotech companies through their
early growth and public listing as well as running large
businesses within major corporations.
We are confident that he
will bring this experience to bear in steering Akubio."